CliffBio
small molecule

OCALIVA

OBETICHOLIC ACID

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyIntercept Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameOCALIVA
Active ingredientOBETICHOLIC ACID
Strength10MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusDISCN

Listed patents

PatentExpiresType
10751349April 2036product
10758549April 2036use U-2945
10052337April 2036product
10047117September 2033use U-1854
9238673June 2033product
10174073June 2033substance
RE48286February 2027substance, product

More from Intercept Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OCALIVA patent cliff — loss of exclusivity April 2036 | CliffBio